Clinical trials: Diabetes type2
Pre-diabetes
Therapeutic Innovation in Type 2 DIABetes (IT-DIAB)
The main objective of the study is to follow prospectively a cohort of patients with pre-diabetes to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new…
- Trial name
- IT-DIAB (NCT01218061)
- Testing
- Pre-diabetes screening
- Where
- France
- Volunteers
- 366 people
- Sponsor
- Nantes University Hospital
Diabetes Mellitus, Gastroparesis
Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People
The purpose of this study is to determine the effects of the drug lixisenatide on blood sugar levels, stomach emptying, blood pressure and heart rate, release of gut hormones and blood flow in the gut after a glucose drink in…
- Trial name
- Lixi (NCT02308254)
- Testing
- Lixisenatide
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Royal Adelaide Hospital
Catecholamine; Overproduction, Catecholamine; Secretion
Sympathetic Activity and Cardiometabolic Complications
Recent studies on catecholamine physiology have shown a direct correlation with arterial hypertension, overcoming the exclusive role in the diagnosis and follow-up of chromaffin tumors.
- Conditions
- Catecholamine; Overproduction, Catecholamine; Secretion, Metabolic Syndrome, Hypertensive Heart Disease
- Trial name
- SYMPACT (NCT04495231)
- Where
- Italy
- Volunteers
- 1,380 people
- Sponsor
- University of Turin, Italy
Diabetes, Type 2
iDecide.Decido: Diabetes Medication Decision Support Study
Two of AHRQ 's consumer-focused guides, "Pills for Type 2 Diabetes" and "Premixed Insulin for Type 2 Diabetes" could be of great use to underserved ethnic and racial minority adults.
- Trial name
- iDecide (NCT01427660)
- Testing
- Community Health Worker Diabetes Education: Print media, CHW Diabetes Education: tailored web site
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- University of Michigan
Adipose Tissue, Brown Adipose Tissue
Cold Induced Activation of Brown Adipose Tissue in Winter Swimmers
This study investigates cold-induced brown fat activation in winter swimmers and not-winter swimmers by skin temperature measures assessed with infra red thermography imaging and skin temperatures.
- Conditions
- Adipose Tissue, Brown Adipose Tissue, Brown Fat, Uncoupling Protein 1
- Trial name
- COLDBAT_WS (NCT03095846)
- Testing
- Cooling
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Diabetes Mellitus
Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.
- Trial name
- NCT00286442
- Testing
- Alogliptin and metformin, Metformin
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 527 people
- Sponsor
- Takeda
Non-alcoholic Steatohepatitis, Type2 Diabetes
To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes
This study was designed to evaluate the effect of Nesinaact on non-alcoholic steatohepatitis through magnetic resonance imaging (MRI)-based proton density-fat fraction (MRI-PDFF) and liver fibroscan in patients with type 2…
- Trial name
- NCT03950505
- Testing
- Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Type 2 Diabetes Mellitus, Lung Diseases, Obstructive
Integration of Guidelines for Comorbidities
Introduction: in the course of the research, the investigators will develop a decision-support system (comorbidity-DSS) consisting (1) a knowledge base (KB) consisting of (a) computer-interpretable clinical guidelines for type 2…
- Conditions
- Type 2 Diabetes Mellitus, Lung Diseases, Obstructive, Osteoporosis, Hypertension
- Trial name
- NCT02928666
- Testing
- DSS for mitigating interactions between recommendations
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Prevalence and Risk Evaluation of Diabetic Complications of the Foot in A Large Canadian Population
The study aims to assess foot complications among patients with diabetes in Canada, using patient data collected during diabetes foot assessments performed by the LMC Chiropody Team between February 27, 2018 and April 17, 2019.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Foot Deformities, Onychauxis
- Trial name
- PEDAL (NCT04327622)
- Where
- Canada
- Volunteers
- 5,084 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Diabetes Mellitus, Type 2
A Study of LY900014 in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 2 diabetes mellitus. The study will be conducted in participants with type 2 diabetes on insulin injection therapy to…
- Trial name
- NCT03305822
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects
The present study was undertaken to assess the efficacy and safety of two different insulin sensitizers (namely Pioglitazone and Metformin) among subjects with type 2 diabetes mellitus (T2DM) in Bangladesh.
- Trial name
- T2DMCT (NCT01589445)
- Testing
- Pioglitazone hydrochloride, Metformin hydrochloride
- Where
- Bangladesh
- Volunteers
- 77 people
- Sponsor
- University of Dhaka
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124573
- Testing
- Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Sleep Disorder, Metabolic Glucose Disorders
Efficiency of a Nursing Intervention in Sleep Hygiene
Background: The relationship between the appearance of insulin resistance phenomena and insufficient or poor-quality sleep is scientifically documented.
- Trial name
- ENISH (NCT03857802)
- Testing
- Sleep hygiene intervention
- Where
- Spain
- Volunteers
- 86 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Diabetes Mellitus Type 2
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator (2) in combination with metformin, compared to that of placebo (metformin monotherapy), in patients with type 2 diabetes mellitus.
- Trial name
- NCT00266253
- Testing
- GK Activator (2), Metformin
- Where
- 47 sites in United States, Australia and 4 more
- Volunteers
- 220 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
Study of Combination Therapy With SYR-322
To determine the efficacy and safety of SYR-322 (alogliptin) 25-mg, once daily (QD), in patients with diabetes when used in combination with insulin.
- Trial name
- NCT01521962
- Testing
- Alogliptin, Insulin
- Where
- 33 sites in Japan
- Volunteers
- 67 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes
This study is a randomized, double-blind, placebo-controlled trial involving 2,500 individuals aged 40-79 with type 2 diabetes (T2D).
- Trial name
- NCT06861062
- Testing
- Vitamin D3, yeast β-glucan
- Where
- 5 sites in China
- Volunteers
- 2,500 people
- Sponsor
- Huazhong University of Science and Technology
Type II Diabetes Mellitus
Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus
Although intensive medical treatment of diabetes has clearly been demonstrated to be worthwhile, it has not been a total success in diabetes treatment for a variety of reasons including lack of response to medication.
- Trial name
- T2DM (NCT00540462)
- Testing
- gastric bypass, sleeve gastrectomy
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Min-Sheng General Hospital
Type 2 Diabetes, Coronary Heart Disease
Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to examine the existence of heart abnormalities in patients with diabetes and the effect of pioglitazone in correcting these abnormalities.
- Trial name
- NCT01588470
- Testing
- pioglitazone
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type2 Diabetes, Heart Failure
Effect of Ertugliflozin on Cardiac Function in Diabetes
The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using echocardiogram in patients with T2D and HF, who…
- Trial name
- ERTU-GLS (NCT03717194)
- Testing
- Ertugliflozin
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Soo Lim
Hyperlipidemia, Type 2 Diabetes
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.
- Trial name
- NCT01607294
- Testing
- ETC-1002
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Esperion Therapeutics, Inc.